News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
217–252
Matches
460
Sources here
19
Companies here
16
Search results Stored financial headlines

Active search

460 matching headlines

Ticker or company: IKAMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Frontier tech research, news & data

This article provides an inventory turnover analysis for Inhibikase Therapeutics, Inc. (IKT), drawing data from SEC EDGAR filings. It presents both annual and quarterly inventory turnover figures, noting that the company's inventory turnover was "—" for all listed periods, indicating a lack of activity …

IKT main company
Sharemaestro market context Trend signal active 52 weeks +27.5% IKT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics

RA Capital Management has filed an initial beneficial ownership statement (Form 3) for Inhibikase Therapeutics, declaring indirect ownership of 25 million common shares. This filing indicates RA Capital owns 10% of Inhibikase Therapeutics. The event date for the ownership was July 10, 2026, with …

IKT main company
Sharemaestro market context Trend signal active 52 weeks +27.5% IKT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen has downgraded Inhibikase Therapeutics (NASDAQ:IKT) from a "sell" to a "strong sell" rating. Despite this downgrade, other analysts maintain a more positive outlook, with a consensus "Buy" rating and an average price target of $5.40. The company, a clinical-stage biotech focused …

IKT main company
Sharemaestro market context Trend signal active 52 weeks +27.5% IKT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

RA Capital (NASDAQ: IKT) reports 25M-share, 15.9% stake in Inhibikase

RA Capital, through its Healthcare Fund, has reported a 15.9% stake in Inhibikase Therapeutics (IKT), holding 25 million shares. This ownership arose from an at-the-market offering on July 10, 2026, and the percentage is calculated based on an updated share count including these newly …

IKT main company
Sharemaestro market context Trend signal active 52 weeks +27.5% IKT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

BlackRock Portfolio Management (NASDAQ: ANIK) discloses 4.1% Anika Therapeutics ownership

BlackRock Portfolio Management LLC has filed an amended ownership report for Anika Therapeutics Inc. common stock, disclosing a 4.1% beneficial ownership stake, totaling 544,710 shares. The firm holds sole voting power over 520,622 shares and sole dispositive power over all 544,710 shares. No single …

ANIK main company
Sharemaestro market context Trend signal active 52 weeks +122.8% ANIK stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Playtika Holding Corp. Announces Second Quarter 2026 Earnings Release and Conference Call Date

Playtika Holding Corp. (NASDAQ: PLTK) announced it will release its second-quarter 2026 financial results on August 6, 2026, before U.S. markets open. Management will host a conference call at 8:30 AM ET on the same day to discuss the results, with a live webcast …

PLTK main company
Sharemaestro market context Trend signal ended 52 weeks -29.3% PLTK stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Playtika updates financial calendar with second-quarter results call schedule

Playtika has updated its financial calendar, announcing that it will release its second-quarter 2026 results before the U.S. market opens on August 6, 2026. Management will host an earnings conference call at 8:30 a.m. ET on the same day. All related materials will be …

PLTK main company
Sharemaestro market context Trend signal ended 52 weeks -29.3% PLTK stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Anika Therapeutics Expands Revolving Credit Facility Agreement

Anika Therapeutics announced it has expanded its revolving credit facility with Bank of America, N.A. The Fifth Amendment establishes a $50 million senior revolving line of credit with a new maturity date of July 10, 2031, and includes an option to increase total commitments …

ANIK main company
Sharemaestro market context Trend signal active 52 weeks +122.8% ANIK stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026

Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will release its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. This will be followed by a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can …

ANIK main company
Sharemaestro market context Trend signal active 52 weeks +122.8% ANIK stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Anika Therapeutics to issue Q2FY26 results on July 29

Anika Therapeutics, Inc. (NASDAQ: ANIK) is set to release its Q2FY26 financial results before the market opens on Wednesday, July 29, 2026. The company will host a conference call at 8:30 a.m. ET to discuss the results and provide business highlights. Investors can access …

ANIK main company
Sharemaestro market context Trend signal active 52 weeks +122.8% ANIK stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context